USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Prostate CancerBladder Cancer
Interventions
OTHER

Imaging: diffusion-weighted MRI

Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases

OTHER

Sinerem (USPIO) enhanced MRI

USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.

Trial Locations (1)

3010

Inselspital, Bern

All Listed Sponsors
collaborator

Swiss National Science Foundation

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT00622973 - USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases | Biotech Hunter | Biotech Hunter